Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma

A. E. Frankel, S. L. Zuckero, A. A. Mankin, M. Grable, K. Mitchell, Y. J. Lee, D. M. Neville, J. H. Woo

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

The recombinant CD3 immunotoxin, A-dmDT390-bisFv(UCHT1), composed of the catalytic and translocation domains of diphtheria toxin fused to two single chain Fv fragments of an anti-CD3ε monoclonal antibody was administered to five patients with cutaneous T cell lymphoma (CTCL) by eight 15 min intravenous infusions over four days. Side effects were fever, chills, nausea, hypoalbuminemia, transaminasemia and reactivation of EBV and CMV. Half-life of drug was 40 min. Anti-immunotoxin antibodies developed in all patients after two weeks. Two patients had partial remissions lasting 1 and 6+ months. The agent is undergoing further dose escalation and shows promising results in this disease.

Original languageEnglish (US)
Pages (from-to)104-109
Number of pages6
JournalCurrent Drug Targets
Volume10
Issue number2
DOIs
StatePublished - 2009

Fingerprint

Immunotoxins
Cutaneous T-Cell Lymphoma
Diphtheria
T-cells
Immunoglobulin Variable Region
Diphtheria Toxin
Single-Chain Antibodies
Hypoalbuminemia
Chills
Monoclonal Antibodies
Human Herpesvirus 4
Intravenous Infusions
Nausea
Half-Life
Antibodies
Anti-Idiotypic Antibodies
Catalytic Domain
Fever
Therapeutics
Pharmaceutical Preparations

Keywords

  • Cutaneous T cell lymphoma
  • Diphtheria toxin
  • Immunotoxin

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Frankel, A. E., Zuckero, S. L., Mankin, A. A., Grable, M., Mitchell, K., Lee, Y. J., ... Woo, J. H. (2009). Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma. Current Drug Targets, 10(2), 104-109. https://doi.org/10.2174/138945009787354539

Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma. / Frankel, A. E.; Zuckero, S. L.; Mankin, A. A.; Grable, M.; Mitchell, K.; Lee, Y. J.; Neville, D. M.; Woo, J. H.

In: Current Drug Targets, Vol. 10, No. 2, 2009, p. 104-109.

Research output: Contribution to journalArticle

Frankel, AE, Zuckero, SL, Mankin, AA, Grable, M, Mitchell, K, Lee, YJ, Neville, DM & Woo, JH 2009, 'Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma', Current Drug Targets, vol. 10, no. 2, pp. 104-109. https://doi.org/10.2174/138945009787354539
Frankel, A. E. ; Zuckero, S. L. ; Mankin, A. A. ; Grable, M. ; Mitchell, K. ; Lee, Y. J. ; Neville, D. M. ; Woo, J. H. / Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma. In: Current Drug Targets. 2009 ; Vol. 10, No. 2. pp. 104-109.
@article{c0e3382aed5b42d3a4dd06d5a193dae1,
title = "Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma",
abstract = "The recombinant CD3 immunotoxin, A-dmDT390-bisFv(UCHT1), composed of the catalytic and translocation domains of diphtheria toxin fused to two single chain Fv fragments of an anti-CD3ε monoclonal antibody was administered to five patients with cutaneous T cell lymphoma (CTCL) by eight 15 min intravenous infusions over four days. Side effects were fever, chills, nausea, hypoalbuminemia, transaminasemia and reactivation of EBV and CMV. Half-life of drug was 40 min. Anti-immunotoxin antibodies developed in all patients after two weeks. Two patients had partial remissions lasting 1 and 6+ months. The agent is undergoing further dose escalation and shows promising results in this disease.",
keywords = "Cutaneous T cell lymphoma, Diphtheria toxin, Immunotoxin",
author = "Frankel, {A. E.} and Zuckero, {S. L.} and Mankin, {A. A.} and M. Grable and K. Mitchell and Lee, {Y. J.} and Neville, {D. M.} and Woo, {J. H.}",
year = "2009",
doi = "10.2174/138945009787354539",
language = "English (US)",
volume = "10",
pages = "104--109",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma

AU - Frankel, A. E.

AU - Zuckero, S. L.

AU - Mankin, A. A.

AU - Grable, M.

AU - Mitchell, K.

AU - Lee, Y. J.

AU - Neville, D. M.

AU - Woo, J. H.

PY - 2009

Y1 - 2009

N2 - The recombinant CD3 immunotoxin, A-dmDT390-bisFv(UCHT1), composed of the catalytic and translocation domains of diphtheria toxin fused to two single chain Fv fragments of an anti-CD3ε monoclonal antibody was administered to five patients with cutaneous T cell lymphoma (CTCL) by eight 15 min intravenous infusions over four days. Side effects were fever, chills, nausea, hypoalbuminemia, transaminasemia and reactivation of EBV and CMV. Half-life of drug was 40 min. Anti-immunotoxin antibodies developed in all patients after two weeks. Two patients had partial remissions lasting 1 and 6+ months. The agent is undergoing further dose escalation and shows promising results in this disease.

AB - The recombinant CD3 immunotoxin, A-dmDT390-bisFv(UCHT1), composed of the catalytic and translocation domains of diphtheria toxin fused to two single chain Fv fragments of an anti-CD3ε monoclonal antibody was administered to five patients with cutaneous T cell lymphoma (CTCL) by eight 15 min intravenous infusions over four days. Side effects were fever, chills, nausea, hypoalbuminemia, transaminasemia and reactivation of EBV and CMV. Half-life of drug was 40 min. Anti-immunotoxin antibodies developed in all patients after two weeks. Two patients had partial remissions lasting 1 and 6+ months. The agent is undergoing further dose escalation and shows promising results in this disease.

KW - Cutaneous T cell lymphoma

KW - Diphtheria toxin

KW - Immunotoxin

UR - http://www.scopus.com/inward/record.url?scp=64249158870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64249158870&partnerID=8YFLogxK

U2 - 10.2174/138945009787354539

DO - 10.2174/138945009787354539

M3 - Article

C2 - 19199905

AN - SCOPUS:64249158870

VL - 10

SP - 104

EP - 109

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 2

ER -